Aviragen Therapeutics (NASDAQ:AVIR) Files An 8-K Other Events
Item 8.01Other Events
On February 13, 2017, Aviragen Therapeutics, Inc. issued a press
release announcing top-line data from its Phase 2b SPIRITUS trial
of vapendavir for the treatment of rhinovirus (RV) in patients
with moderate to severe asthma. A copy of the press release is
attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
99.1 |
Press release dated February13, 2017. |
|
About Aviragen Therapeutics (NASDAQ:AVIR)
Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases. Aviragen Therapeutics (NASDAQ:AVIR) Recent Trading Information
Aviragen Therapeutics (NASDAQ:AVIR) closed its last trading session down -0.06 at 1.08 with 397,384 shares trading hands.
